Juno Therapeutics, Inc. (NASDAQ:JUNO) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a report issued on Wednesday.

According to Zacks, “Juno remains on track with its pipeline candidates and continues to pursue acquisitions and licensing agreements. The company’s deal with Celgene for the global development and commercialization of immunotherapies is encouraging. Juno’s shares outperformed the Medical-Biomed/Genetics industry so far this year. However, the company recently suffered a huge setback as it discontinued the development of cancer candidate, JCAR015 due to the toxicity witnessed in a phase II ROCKET study. Moreover, increased competition in the immunotherapy space is a matter of concern for the company as several companies are looking to bring these treatments to the market. Estimates have been going up lately ahead of the company’s Q2 earnings release. The company has negative record of earnings surprises in recent quarters.”

Several other research firms have also weighed in on JUNO. BidaskClub upgraded shares of Juno Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Tuesday, June 27th. Vetr upgraded shares of Juno Therapeutics from a “sell” rating to a “hold” rating and set a $28.85 target price on the stock in a report on Tuesday, July 4th. FBR & Co cut their target price on shares of Juno Therapeutics from $30.00 to $29.00 and set a “mkt perform” rating on the stock in a report on Friday, May 5th. Wedbush reiterated a “neutral” rating and issued a $24.00 target price on shares of Juno Therapeutics in a report on Friday, May 5th. Finally, Leerink Swann reiterated an “outperform” rating and issued a $34.00 target price on shares of Juno Therapeutics in a report on Tuesday, June 20th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $30.20.

Juno Therapeutics (NASDAQ:JUNO) traded down 1.69% during trading on Wednesday, reaching $29.11. 1,666,339 shares of the company’s stock traded hands. Juno Therapeutics has a 12 month low of $17.52 and a 12 month high of $35.04. The company’s market cap is $3.03 billion. The firm’s 50 day moving average is $24.94 and its 200 day moving average is $22.57.

Juno Therapeutics (NASDAQ:JUNO) last posted its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.70) by $0.01. The firm had revenue of $19.30 million during the quarter, compared to analyst estimates of $16 million. Juno Therapeutics had a negative return on equity of 24.57% and a negative net margin of 288.66%. The company’s revenue for the quarter was up 96.9% on a year-over-year basis. During the same quarter last year, the business posted ($0.78) earnings per share. Analysts anticipate that Juno Therapeutics will post ($2.99) EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another site, it was illegally copied and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/07/09/juno-therapeutics-inc-nasdaqjuno-upgraded-to-hold-at-zacks-investment-research.html.

In other Juno Therapeutics news, Director Anthony B. Evnin bought 9,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 20th. The stock was acquired at an average price of $24.40 per share, with a total value of $219,600.00. Following the completion of the transaction, the director now owns 66,301 shares in the company, valued at $1,617,744.40. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Steve Harr sold 8,750 shares of the firm’s stock in a transaction on Tuesday, June 27th. The shares were sold at an average price of $30.00, for a total transaction of $262,500.00. Following the completion of the transaction, the chief financial officer now directly owns 736,189 shares of the company’s stock, valued at approximately $22,085,670. The disclosure for this sale can be found here. In the last ninety days, insiders sold 41,500 shares of company stock valued at $1,230,360. 15.26% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Teachers Advisors LLC increased its position in Juno Therapeutics by 5.8% in the first quarter. Teachers Advisors LLC now owns 64,365 shares of the biopharmaceutical company’s stock worth $1,428,000 after buying an additional 3,531 shares during the period. Great West Life Assurance Co. Can increased its position in Juno Therapeutics by 80.5% in the first quarter. Great West Life Assurance Co. Can now owns 8,518 shares of the biopharmaceutical company’s stock worth $189,000 after buying an additional 3,800 shares during the period. Opus Point Partners Management LLC increased its position in Juno Therapeutics by 65.9% in the fourth quarter. Opus Point Partners Management LLC now owns 11,478 shares of the biopharmaceutical company’s stock worth $216,000 after buying an additional 4,560 shares during the period. Baird Financial Group Inc. increased its position in Juno Therapeutics by 25.7% in the first quarter. Baird Financial Group Inc. now owns 28,583 shares of the biopharmaceutical company’s stock worth $634,000 after buying an additional 5,839 shares during the period. Finally, State Board of Administration of Florida Retirement System increased its position in Juno Therapeutics by 11.9% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 67,000 shares of the biopharmaceutical company’s stock worth $1,263,000 after buying an additional 7,137 shares during the period. 64.53% of the stock is owned by institutional investors and hedge funds.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Get a free copy of the Zacks research report on Juno Therapeutics (JUNO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.